Update on genistein trial for patients with MPSIII Sanfilippo


Microscope icon representing research and treatment

Update on genistein trial for patients with MPSIII Sanfilippo

High dose genistein treatment in children with Sanfilippo disease shows no clinically meaningful benefit A Phase III, Double Blinded, Randomised, Placebo Controlled Clinical Trial of High Dose Oral Genistein Aglycone in Patients with Sanfilippo Syndrome (Mucopolysaccharidosis III A, B and

New Board for IMPSN

New beginnings for the international MPS network

Meeting in San Diego at the 15th International Symposium on MPS and related diseases, over 20 of the 40 patient organisations that form the International MPS Network (IMPSN) came together to breathe new life into the group. The aim of

BioMarin logo

Update on the BioMarin Sanfilippo Syndrome Type B (MPS IIIB) Clinical Development Program

An Update for Patient Associations and Families from BioMarin May 2018 We would like to update you about the status of our clinical development program in Sanfilippo B. The BioMarin program, which involves multiple centers around the world, consists of

Europe logo

Stand on your own – Adult MPS patient meeting in Germany

This fellowship has now closed and is not accepting any more applications. Adult  MPS  patients  meeting STAND  ON  YOUR  OWN October  4  and  5,  2018 Maritim  Hotel  Gelsenkirchen,  Germany  For  the  first  time  MPS  Europe  is  organising  Adult  MPS  patients

Sangamo logo

Sangamo Announces Treatment of First Patient in Phase 1/2 Clinical Trial Evaluating SB-318 Investigational in Genome Editing Therapy for MPS I

The EMPOWERS Study is an open-label, ascending dose clinical trial designed to assess the safety, tolerability and preliminary efficacy of SB-318 in up to nine adult subjects with attenuated MPS I. The study is currently screening subjects at hospitals specializing